Ranking: Baxter, J&J lead green pharma companies

Baxter ($BAX) leads public-company drugmakers in Newsweek's annual top 500 global sustainability ratings. Finishing in the 24th spot, it edged out Johnson & Johnson ($JNJ) in 26th place and Novartis ($NVS) in 34th.

To rank companies, Newsweek considers their environmental footprint, green management initiatives and sustainability communications.

AstraZeneca ($AZN), 62nd, and Novo Nordisk ($NVO), 72nd, round out drugmakers in the top 100.

Roche ($RHHBY) and Pfizer ($PFE) finished next among big pharma, at 103rd and 106th, respectively. Bayer ($BAY), Sanofi ($SNY), Bristol-Myers Squibb ($BMY), Eli Lilly ($LLY), Merck KGaA, GlaxoSmithKline ($GSK), Merck U.S. ($MRK), Abbott ($ABT) and Teva ($TEVA) all finished in the top 500.

Among its overall findings: Momentum behind green initiatives has "seriously stalled, at least in the public sector," largely due to the economy.

- see the ranking
- here's the story

Special Report: The 12 greenest companies in biopharma

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.